Anti-CYP4F2 / Cytochrome P450 4F2

Adding 0.2 ml of distilled water will yield a concentration of 500 ug/ml. CYP4F2 antibody detects Cytochrome P450 4F2, encoded by the CYP4F2 gene on chromosome 19p13.12. CYP4F2 antibody is widely used to study this endoplasmic reticulum-anchored monooxygenase belonging to the cytochrome P450 superfamily. CYP4F2 catalyzes hydroxylation of bioactive lipids, including leukotriene B4, arachidonic acid, and vitamin K, connecting it to inflammation, vascular tone, and coagulation. Its expression is highest in the liver and kidney, but it is also detected in vascular tissues and immune cells, reflecting diverse physiological roles.Structurally, CYP4F2 is a 60 kDa heme-containing protein. Its conserved P450 fold positions the heme prosthetic group for electron transfer from NADPH-cytochrome P450 reductase, enabling substrate hydroxylation. Substrate specificity is determined by the hydrophobic active site pocket, which accommodates long-chain fatty acids and lipid mediators. Regulatory input from nuclear receptors such as PXR, CAR, and VDR ensures CYP4F2 responds dynamically to xenobiotics, hormones, and metabolic cues.Functionally, CYP4F2 terminates leukotriene B4 signaling by omega-hydroxylation, preventing excessive inflammation. It also converts arachidonic acid to 20-HETE, a metabolite regulating vascular tone, renal sodium handling, and blood pressure. Hydroxylation of vitamin K affects coagulation factor activity, directly influencing anticoagulant therapy with warfarin. Genetic polymorphisms in CYP4F2, such as V433M, alter enzymatic activity and are clinically important in warfarin dosing and cardiovascular disease susceptibility. Researchers employ CYP4F2 antibody to analyze these pathways in pharmacogenetics and vascular biology.Clinically, CYP4F2 variants are linked to hypertension, stroke, and altered warfarin sensitivity. Dysregulation may also contribute to metabolic syndrome and chronic kidney disease through disrupted lipid mediator balance. In oncology, altered CYP4F2 expression modulates tumor microenvironment signaling, influencing angiogenesis and progression. Its integration of lipid metabolism with vascular and immune function underscores its significance in health and disease. NSJ Bioreagents supplies CYP4F2 antibody as a validated reagent for pharmacology, cardiovascular, and metabolic research.Experimentally, CYP4F2 antibody is used in western blotting to detect protein levels, in immunohistochemistry to visualize tissue distribution, and in immunofluorescence to track subcellular localization. Immunoprecipitation with CYP4F2 antibody confirms interactions with P450 reductase and cytochrome b5. These approaches support investigations into lipid metabolism and drug response. NSJ Bioreagents provides CYP4F2 antibody to ensure consistent results in research and clinical studies.